Abivax (ABVX) Skyrockets 24% After Steep Fall
Abivax soared by 24.34 percent on Wednesday to close at $90.15 apiece, as investors resorted to bargain-hunting to take advantage of its low price following its...
America Forever Bytes
Abivax · AFBytes
Company
Abivax
Recent coverage
Top Biotech Gainers: ABVX, CING, DRTS, MMED...
Today's gainers list includes ABIVAX, which recently announced positive ulcerative colitis trial results; Cingulate, which is working toward resubmission of a N...
Abivax Grounded as Cancer Cases Cast a Shadow Over Best-in-Class Trial Data
The French biotech’s landmark late-stage trial hit its goals out of the park, but a cluster of high-dose safety concerns has triggered a brutal market correct...
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street
ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis